Quantcast
Last updated on April 24, 2014 at 17:35 EDT

FDA Warns on Propecia Sexual Dysfunction: Threat Remains

May 1, 2012

On April 11th, 2012, the U.S. FDA announced changes to the labels for Propecia (finasteride) and Proscar to expand the list of sexual adverse events reported to FDA as some of these events have been reported to continue after the drug is no longer being used. Propecia is a pill, manufactured by Merck, for use in males only and indicated for the treatment of male pattern hair loss. It was approved by the FDA in 1997. On April 16th, 2012, sixteen federal lawsuits that alleged persistent sexual dysfunction caused by Propecia, were centralized in New York. The Propecia MDL (MDL Docket No. 2331) was sent to the U.S. District Court for the Eastern District of New York with similar allegations in the lawsuits; Merck failed to warn on Propecia side effects that could cause permanent and devastating sexual dysfunction. Now, AttorneyOne.com, a recognized authority on law, can provide helpful, proven advice and simple solutions including how to get in contact with legal counsel so anyone can easily and inexpensively deal with cases of Propecia severe adverse events. [http://www.attorneyone.com/propecia-causes-impotence/ .

San Diego, CA (PRWEB) May 01, 2012

The media spotlight is often a double-edged sword. No one knows this better than men who suffer from Propecia sexual dysfunction. And yet, gossip and rumor-mongering aside, the real story here is being overlooked according to Sean Burke of AttorneyOne.

On April 11th, 2012, the U.S. FDA announced changes to the labels for Propecia (finasteride) and Proscar to expand the list of sexual adverse events reported to FDA as some of these events have been reported to continue after the drug is no longer being used. Propecia is a pill manufactured by Merck & Co and approved by FDA in 1997. The drug is for use in males only and indicated for the treatment of male pattern hair loss. The revision to the Propecia label will include libido disorders, ejaculation disorders, and orgasm disorders that continued after discontinuation of the drug.

According to court documents, on April 16th, 2012, sixteen federal lawsuits on Propecia persistent sexual dysfunction were centralized in New York. The Propecia MDL (MDL Docket No. 2331) was sent to the U.S. District Court for the Eastern District of New York, before Federal Judge John Gleeson. The allegations included in the lawsuits are similar: Merck failed to adequately warn that side effects of Propecia could cause permanent and devastating sexual dysfunction, such as erectile dysfunction, infertility, loss of libido and impotence.

AttorneyOne.com, a recognized authority on law, can provide helpful advice and simple solutions including how to get in contact with legal counsel so that, in case of Propecia sexual dysfunction, someone can easily and inexpensively deal with it. As Mr. Burke, director of Media Relations for AttorneyOne.com, added, “What all this information really illustrates is that threat from Propecia remains. For that reason, our focus should squarely fall on getting the word out and assisting people in finding the right legal assistance.”

Before the announcement on the Propecia label change, FDA reviewed 421 postmarketing reports of sexual dysfunction submitted to the Agency´s Adverse Events Reporting System (AERS) database between 1998 and 2011. Of these, 59 cases reported sexual dysfunction that lasted for at least three months following discontinuation of Propecia, and included erectile dysfunction, decreased libido, problems with ejaculation and orgasm disorders.

AttorneyOne.com has further information on Propecia lawsuits including how to get in contact with legal counsel.

Headquartered in San Diego, CA Attorney One was founded in 2004 and is not a law firm. They offer a nationwide legal service which helps consumers find the best representation for their legal needs. You can learn more about Propecia at our website. You can also find us on Facebook at http://www.facebook.com/AttorneyOne. Checkout earlier news from us at http://www.prweb.com/releases/2012/4/prweb9454670.htm.

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/5/prweb9458683.htm


Source: prweb